<sup>18</sup>F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO - Concepedia

Concepedia

Publication | Open Access

<sup>18</sup>F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO

DOI Full Paper Access

157

Citations

33

References

2013

Year

Géraldine Gebhart, Cristina Gámez‐Cenzano, Eileen Holmes, Javier Robles, Camilo Garcia, Montserrat Cortés, Evandro de Azambuja, Karine Fauria, Veerle Van Dooren, Gursel Aktan,

Journal of Nuclear Medicine

Abstract

Early metabolic assessment using (18)F-FDG PET/CT can identify patients with an increased likelihood of pCR after neoadjuvant trastuzumab, lapatinib, or their combination when given with chemotherapy.

References

	Year	Citations

Page 1